The top-line beat was led by its higher than anticipated sales of Covid-19 vaccine, while its recently approved respiratory syncytial virus vaccine raked in just $10 ...

With the possibility of RFK Jr. being involved in health policy in the next administration, vaccination, especially mRNA ...

Working with mice, hamsters, and nonhuman primates, Penn researchers found that a modified version of the mRNA COVID-19 ...

Moderna (MRNA) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $1.89 per share. This compares to loss of $1.39 per share a year ago. These ...

Moderna reported a surprise third-quarter profit on Thursday, driven by cost cutting and higher-than-expected sales of its COVID-19 vaccine, even with low revenue from its new respiratory syncytial ...

Moderna Chief Human Resources Officer Tracey Franklin has expanded her role to Chief People and Digital Technology Officer, overseeing the Company's talent and digital functions. Brad Miller, Chief ...

A new study shows that a biomedical tool can successfully deliver genetic material to edit faulty genes in developing fetal ...

Repeated mRNA vaccinations boost mucosal antibodies, improving defense against COVID-19. This may help enhance protection ...

CureVac (CVAC) has released an update. CureVac is set to unveil promising new data from its mRNA-based cancer vaccine study at the upcoming ...

Singapore has launched Asia's first automated mRNA manufacturing facility, which will speed up vaccine production in the ...

Researchers are exploring a new mRNA delivery technique to treat genetic conditions in the fetal brain, potentially ...

Working with animals, Penn researchers modified the mRNA vaccine to target C. difficile, an infection that kills 30,000 in ...